FindTrial
Sign In

SGT-53

GENETIC6 trials

Sponsors

SynerGene Therapeutics, Inc., Children's National Research Institute

Conditions

ATRT RecurrentCNS MalignanciesChildhood CNS TumorEmbryonal NeoplasmEpendymoma RecurrentHigh Grade GliomasMedulloblastoma RecurrentMetastatic Pancreatic Cancer

Early Phase 1

SGT-53 in Children With Recurrent or Progressive CNS Malignancies
WithdrawnNCT03554707
SynerGene Therapeutics, Inc.Childhood CNS Tumor
Start: 2022-06-01End: 2022-06-01Updated: 2026-05-08
A Phase 0/1 Study of cDNA for TP53, Checkpoint Inhibition and Radiation in Children With Recurrent, Progressive or Refractory CNS Malignancies.
RecruitingNCT07017816
Children's National Research InstituteATRT Recurrent, CNS Malignancies, Embryonal Neoplasm +4
Start: 2025-12-16End: 2028-05-01Target: 18Updated: 2026-04-29

Phase 1

Safety Study of Infusion of SGT-53 to Treat Solid Tumors
CompletedNCT00470613
SynerGene Therapeutics, Inc.Neoplasm
Start: 2008-02-29End: 2016-12-31Updated: 2017-04-26
A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors
SuspendedNCT02354547
SynerGene Therapeutics, Inc.Neoplasm
Start: 2014-12-01End: 2027-12-01Target: 18Updated: 2026-05-08

Phase 2

Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma
TerminatedNCT02340156
SynerGene Therapeutics, Inc.RECURRENT GLIOBLASTOMA
Start: 2014-12-31End: 2018-11-30Updated: 2021-03-03
Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer
Active, not recruitingNCT02340117
SynerGene Therapeutics, Inc.Metastatic Pancreatic Cancer
Start: 2015-01-31End: 2026-12-31Target: 28Updated: 2025-05-30

Related Papers

A phase II trial combining tumor-targeting <i>TP53</i> gene therapy with gemcitabine/nab-paclitaxel as a second-line treatment for metastatic pancreatic cancer.
Journal of Clinical Oncology2021-05-2015 citations